Rac and its downstream effectors p21-activated kinase (PAK) family kinases regulate actin dynamics within growth cones to control neurite outgrowth during development. The activity of Rac is stimulated by guanine nucleotide exchange factors (GEFs) that promote GDP release and GTP binding. ALS2/Alsin is a recently described GEF that contains a central domain that is predicted to regulate the activities of Rac and/or Rho and Cdc42 activities. Mutations in ALS2 cause some recessive familial forms of amyotrophic lateral sclerosis (ALS) but the function of ALS2 is poorly understood. Here we demonstrate that ALS2 is present within growth cones of neurons, in which it co-localizes with Rac. Furthermore, ALS2 stimulates Rac but not Rho or Cdc42 activities, and this induces a corresponding increase in PAK1 activity. Finally, we demonstrate that ALS2 promotes neurite outgrowth. Defects in these functions may therefore contribute to motor neuron demise in ALS.
domain that displays homology to the Ran GEF RCC1; a central region containing Dbl and pleckstrin homology (DH/PH) domains that are found in GEFs for Rho, Rac, and Cdc42; and a carboxyl-terminal vacuolar protein-sorting 9 (VPS9) domain that is found in GEFs for Rab5 (5, 6) . Indeed, there is now evidence that ALS2 functions as a GEF, including one for Rab5 that is via its VPS9 domain (12) (13) (14) (15) .
The mechanisms by which mutant ALS2 induces disease are poorly understood. One possibility is that there are links between ALS2 and mutant SOD1 and that there are common pathways of toxicity (15, 16) . However, the recessive nature and types of mutations in affected families strongly suggest that a loss of ALS2 function is the primary cause of disease. Indeed, at least some of the mutants generate unstable forms of the protein (17) . A proper understanding of the molecular mechanisms by which mutant ALS2 induces motor neuron disease thus requires insight into ALS2 function. Here we demonstrate that ALS2 stimulates Rac1-p21-activated kinase (PAK) signaling and is involved in neurite outgrowth.
EXPERIMENTAL PROCEDURES
Plasmids and Mutagenesis-A carboxyl-terminal myc-tagged human ALS2 cDNA was generated by PCR. Briefly, the 5Ј-end of ALS2 was amplified by PCR from a human brain cDNA library and ligated to a 5Ј-truncated partial ALS2 cDNA (clone KIAA1563) so as to create a full-length clone. A carboxyl-terminal myc tag was then added by PCR, and the tagged full-length cDNA was then cloned into pCIneo (Promega) as a NotI fragment. A mutant ALS2 clone (ALS2⌬DH) in which the DH/PH GEF domain was disrupted was created by the deletion of sequences encoding the DH domain (residues 747-826). Sequences were deleted using an ExSite mutagenesis kit (Stratagene) with primers 5Ј-ACTCAGTTGATGGAAATACTGAATAC-3Ј and 5Ј-ACACAG-CTTGCTGAATCGGCTAGC-3Ј. ALS2 phosphorylation sites were altered using a QuikChange Multi site-directed mutagenesis kit (Stratagene) and primers 5Ј-GCCAGCACTGCTCTCGCCCCCTCCACT-GAAACC-3Ј (S277A), 5Ј-GATTGTTGTCACAAGTTGCCCCCAG-GCTCTTAAG-3Ј (S492A), 5Ј-GAGGACAGTGGTTCTGGCCCCC-ACATACAGTGG-3Ј (T510A), 5Ј-GCCAGCACAGAGACGCTCCA-GAAATATTGAGTCG-3Ј (S1335A), and 5Ј-GATTCCCGATCTGA-AGCACCAGAGCCAGGTTATG-3Ј (S1464A). The DH/PH GEF domain (amino acids 681-1010) of ALS2 was generated by PCR and cloned as a BamHI-EcoRI fragment into pRK5myc. RhoA, Rac1, L61Rac1 (constitutively active Rac1), N17Rac1 (dominant-negative Rac1), Cdc42, and N39Rab5 (dominant-negative Rab5) were all expressed using pRK5myc variants. pCMV6myc-PAK1 clone was obtained from Sashi Kesavapany (National Institutes of Health, Bethesda, MD). Vector pCIneoCAT expressing the Escherichia coli chloramphenicol acetyl transferase gene (18) was used as a control for comparisons of the effects of ALS2 expression on GTPase and PAK1 activities and neurite outgrowth. Plasmid pEGFPC.1 was obtained from Clontech.
Antibodies-Sequences encoding residues 452-668 of ALS2 were amplified by PCR using primers 5Ј-GCGGAATTCGAACAGGTTA-AACAGGAATCAATGC-3Ј and 5Ј-GCGGAATTCTCCAAGCT-TACTACAGGAGAGAAG-3Ј and cloned into pGEX5X1 as an EcoRI fragment. Glutathione S-transferase (GST)-ALS2-(452-668) was expressed in E. coli BL21-CodonPlus(DE3)RIL, purified essentially according to the manufacturer's instructions (Amersham Biosciences), and used to immunize rabbits. The ALS2 antibody was affinity-purified against antigen prior to use. Antibodies to PAK1 and to myc tags (antibody 9B11) were obtained from New England Biolabs; Rac, Rho(A,B,C), and Cdc42 antibodies were from Upstate; Rab5 antibody was from BD Biosciences; ␣-tubulin antibody (DM1A) was from Sigma; AlexaFluor 568-phalloidin was from Molecular Probes.
Cell Culture and Transfection-CHO cells were grown in HAM's F-12 medium containing 10% (v/v) fetal bovine serum supplemented with 2 mM glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin (Invitrogen). Cells were transfected using Lipofectamine (Invitrogen) according to the manufacturer's instructions. Primary cortical and hippocampal neurons were obtained from embryonic day 18 rat embryos and cultured on glass coverslips coated with poly-D-lysine in 12-well plates (Falcon) in neurobasal medium and B27 supplement (Invitrogen) containing 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM glutamine. Neurons were transfected using Lipofectamine 2000 (Invitrogen) as described previously (19) .
SDS-PAGE and Immunoblotting-Samples were processed for SDS-PAGE by the addition of SDS-PAGE sample buffer and heating immediately in a boiling water bath. Proteins were separated on 10% (w/v) acrylamide gels and transferred to Protran nitrocellulose membranes (Schleicher & Schuell) using a Bio-Rad TransBlot system. Following blocking and probing with primary antibodies, the blots were washed and incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit Ig (Amersham Biosciences) and developed using an enhanced chemiluminescence system (Amersham Biosciences) according to the manufacturer's instructions.
GTPase and PAK1 Assays-Cellular Rho, Rac, and Cdc42 activities were assayed using commercially available kits essentially according to the manufacturer's instructions (Upstate Biotechnology). Briefly, CHO cells were co-transfected with RhoA, Rac1, or Cdc42 in combination with ALS2 plasmids or vector encoding CAT (pCIneoCAT) as a negative control. Cells were harvested into ice-cold lysis buffer (composed of 25 mM HEPES (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 10 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 1 mM NaF, 1 mM sodium orthovanadate, and complete protease inhibitor mixture (Roche Applied Science)) 24 h posttransfection and following 16 h of serum starvation. Active (GTPbound) Rho, Rac, and Cdc42 were captured on GST-bait beads. Active Rho was captured using GST-rhotekin Rho-binding domain (GST-RBD) and active Rac and Cdc42 captured using GST-PAK1 p21-binding domain (GST-PBD). Captured Rho, Rac, and Cdc42 were detected on immunoblots, and the relative amounts were quantified by pixel densitometry using a Bio-Rad GS710 imaging densitometer and Quantity 1 software as described previously (20) .
PAK1 activities in transfected CHO cells were assayed essentially as described previously by us for other kinases (21, 22) . Briefly, cells were co-transfected with PAK1, Rac, and ALS2, ALS2⌬DH, or vector encoding CAT as a negative control. For a positive control, cells were cotransfected with PAK1 and a constitutively active Rac (L61Rac1). Cells were harvested into ice-cold lysis buffer (composed of 20 mM HEPES (pH 7.4), 2mMEGTA, 1% Triton X-100, 10% glycerol, 1 mMdithiothreitol, 1 mMsodium orthovanadate, 50 mM ␤-glycerophosphate, and complete protease inhibitor mixture (Roche Applied Science)), and following preclearing of the samples, PAK1 was isolated by immunoprecipitation. In vitro kinase assays were performed at 30°C in 25 mM HEPES, 20 mM MgCl 2 , 20 mM ␤-glycerophosphate, 20 mM p-nitrophenylphosphate, 0.1 mM sodium orthovanadate, 2 mM dithiothreitol, 0.26 MBq [-32 P]ATP, 20 M ATP, and 5 g of myelin basic protein as substrate in a final volume of 30 l. The reactions were terminated after 20 min (which pilot studies had demonstrated was within the linear range of PAK1 activity) by the addition of SDS-PAGE sample buffer and heating in a boiling water bath, and the samples were separated by SDS-PAGE. The gels were stained with Coomassie Blue, and a radioactive signal was detected using Fujix BAS1000 phosphorimaging with a BAS reader and TINA 2.07 software and by autoradiography. A proportion of the reaction was also probed for immunoprecipitated PAK1 on immunoblots so as to demonstrate equal amounts of kinase in the different transfections.
Immunofluorescence Studies and Neurite Length MeasurementsNeurons grown on coverslips were fixed in 4% (w/v) paraformaldehyde in Tris-HCl-buffered saline (TBS) for 20 min, permeabilized in 0.1% (w/v) Triton X-100 in TBS for 10 min, blocked with 5% (v/v) goat serum/0.2% (w/v) Tween 20 in TBS for 1 h, and then probed with primary antibodies diluted in blocking solution. Primary antibodies were then detected using goat anti-mouse or goat anti-rabbit Ig coupled to AlexaFluor 350 or AlexaFluor 546 (Molecular Probes), and the samples were mounted in Vectashield (Vector Laboratories).
For analyses of the effects of ALS2 on neurite outgrowth, 2 DIV cortical neurons were co-transfected with plasmid pEGFPC.1 (Clontech) expressing enhanced green fluorescent protein (GFP) plus experimental or control plasmids. GFP was used to determine cell shape because it has been shown to distribute uniformly throughout neurons and has been used as a marker for neuronal cell shape in numerous studies (e.g. Refs. 23 and 24). Experimental and control plasmids included ALS2, ALS2⌬DH, dominant-negative N17Rac and N39Rab5, and vector expressing pCIneoCAT, which was used to balance transfections so that all cells received the same numbers and amounts of plasmid. All of the GFP-expressing cells were immunostained for co-transfected protein to FIGURE 1. ALS2 stimulates Rac activity. Rho, Rac, and Cdc42 activation assays were conducted in CHO cells transfected with Rho, Rac, or Cdc42, ϩ ALS2 or control vector pCIneoCAT (CAT). A, representative assays for the three GTPases. Active Rho was pulled down from the lysates using GST-RBD, and active Rac and Cdc42 were pulled down with GST-PBD. The bound Rho, Rac, and Cdc42 were then detected by immunoblotting (Active). The amounts of Rho, Rac, and Cdc42 transfected into the cells were also detected by immunoblotting so as to demonstrate equal transfection efficiencies (Total). GST alone did not bind any GTPase in the transfected cells. B, disruption of the ALS2 Rac GEF domain (in ALS2⌬DH) abrogates the stimulatory effect on Rac activity. C, histogram of fold increases in GTPase activity that were obtained from four separate experiments for each GTPase. Error bars are S.E. One-way analysis of variance tests showed that ALS2 significantly increased Rac activity by 3.3-fold (p Ͻ 0.001) but not Rho or Cdc42 activities.
ALS2 Stimulates Neurite Outgrowth
confirm expression. Only healthy cells as judged by morphology (including nuclear staining with Hoechst 33258 (Sigma) to confirm that nuclei had a nonapoptotic appearance) were analyzed. Cells were analyzed 24 h later; the analysis included counting the numbers and measuring the lengths of axons and dendrites. However, only the longest neurite in each cell was used in the comparisons, which is similar to the methods used in numerous other studies on the effects of signaling cascades on neurite outgrowth (e.g. Refs. 25 and 26). Cells were analyzed without knowledge of the transfected plasmids.
Conventional images were captured using a Zeiss Axioscop microscope and charge-coupled device camera (Princeton Instruments), and confocal images were captured using a Zeiss LSM 510 META confocal microscope. Images for neurite outgrowth experiments were analyzed using MetaMorph image analysis software. Neurite lengths were determined as the distance from the edge of the cell body to the growth cone tip.
Mass Spectrometric Sequencing of ALS2-ALS2 was isolated by immunoprecipitation and sequenced to identify phosphorylation sites, essentially as described by us for other proteins (18, 27) . Briefly, ALS2 was immunoprecipitated from transfected CHO cells by use of the myc tag and then isolated by excision of bands after SDS-PAGE. Bands were reduced, alkylated, and digested with trypsin, chymotrypsin, or Asp-N (Roche Applied Science), and peptides were extracted with two wash cycles of 50 mM NH 4 HCO 3 and acetonitrile and then lyophilized and resuspended in 20 l of 50 mM NH 4 HCO 3 .
Peptide digests were analyzed by on-line liquid chromatography tandem mass spectrometry. Peptides were ionized by electrospray ionization using a Z-spray source fitted to a QTof-micro mass spectrometer (Micromass UK). The instrument was set to run in automated switching mode, selecting precursor ions based on their intensity and charge state, for sequencing by collision-induced fragmentation. The tandem mass spectrometry analyses were conducted using collision energy profiles that were chosen based on the mass/charge (m/z) and the charge state of the peptide and optimized for phosphorylated peptides.
The mass spectral data were processed into peak lists containing the m/z value of each precursor ion and the corresponding fragment ion m/z values and intensities. Data were searched against a custom-built data base containing the full-length sequence of ALS2 using the Mascot searching algorithm (Matrix Science). Peptides and phosphopeptides of ALS2 were identified as described previously (18, 27) .
Statistical Analyses-Statistical significance for GTPase and PAK1 activities and for neurite outgrowth was determined using one-way analysis of variance followed by Tukey post-hoc tests for pairwise comparison. Differences were considered significant at p Ͻ 0.05.
RESULTS

ALS2
Stimulates Rac1-PAK1 Signaling-ALS2 contains a central DH/PH domain that shows homology to GEFs that regulate Rho, Rac, and Cdc42 GTPases. To determine whether ALS2 activates these GTPases, we utilized in vivo pull-down assays to monitor the activities of RhoA, Rac1, and Cdc42 GTPases in transfected CHO cells. Active (GTP-bound) Rho binds to rhotekin, whereas active Rac and Cdc42 both bind PAK1. GST-RBD and GST-PBD "baits" can thus be used to isolate GTP-bound RhoA, Rac1, and Cdc42 from experimentally manipulated cells; the amounts of these GTPases detected on immunoblots correlates with their activities (28, 29) .
Co-transfection of cells with ALS2 induced a significant (3.3-fold) increase in the amount of Rac1 but not Cdc42 pulled down by GST-PBD bait. Although a small increase in the amount of Rho pulled down by GST-RBD bait was also observed in ALS2-co-transfected cells, this was not statistically significant (Fig. 1A) . To confirm that the stimulatory effect on Rac activity was indeed mediated by the DH/PH domain, we created an ALS2 mutant (Fig. 1B, ALS2⌬DH ) in which the majority of the catalytic DH domain (residues 747-826) was deleted. This mutant did not activate Rac (Fig. 1B) . However, the isolated DH/PH GEF domain (residues 681-1010) similarly did not activate Rac1 in these assays, which suggests other regions of ALS2 may be necessary for control of its Rac GEF function (supplemental data, Fig. S1 ). Thus, ALS2 stimulates Rac1 activity, and this stimulation requires the full-length ALS2 holoprotein. Recently, others have also shown that ALS2 stimulates Rac activity (13, 15) .
Immediate downstream targets for Rac include members of the PAK family of serine/threonine kinases (30). PAK1 is a major neuronal member of the PAK family. We therefore inquired whether ALS2 also stimulated PAK1 activity. In vitro PAK1 assays were performed from CHO cells cotransfected with PAK1 Ϯ ALS2. These experiments revealed that ALS2 stimulated PAK1 activity but that this stimulation was lost in cells co-transfected with the nonfunctional mutant ALS2⌬DH, which indicates that this activity is dependent on a functional DH/PH (Rac GEF) domain (Fig. 2) . Thus, ALS2 functions as a GEF to regulate Rac1-PAK1 signaling.
ALS2 Is Present in Neuronal Growth
Cones and Co-localizes with Rac-Rho, Rac, and Cdc42 GTPases play a major role in organizing the cytoskeleton and in particular the actin cytoskeleton (11, 30) . In developing neurons, Rho, Rac, and Cdc42 are present in growth cones of axons and dendrites, in which they regulate actin dynamics to control neurite outgrowth. In some paradigms, Rac and Cdc42 promote neurite outgrowth, whereas Rho inhibits it (30 -34) . PAK1 is also present within the growth cone where it too can function in neurite outgrowth, although its precise role may depend upon the stage and type of neuron (30) . We therefore studied developmental expression and also the subcellular distribution of ALS2 in rat cortical and hippocampal neurons. Immunoblots of mouse brains aged from embryonic day 15 (Fig. 3A,   FIGURE 2 . ALS2 stimulates PAK1 activity. PAK1 in vitro kinase assays were performed with CHO cells co-transfected with PAK1, Rac1, and ALS2, ALS2⌬DH, or vector pCIneoCAT (CAT). For a positive control, cells were co-transfected with a constitutively active Rac1 (L61Rac). Ϫ and ϩ refer to the absence or presence of PAK1 immunoprecipitating antibody in the reactions; reaction mix (RM) contains no immunoprecipitation sample. The top panel shows the Coomassie-stained gel with myelin basic protein substrate (MBP), and the middle panel shows the corresponding autoradiograph of the samples. Also shown are levels of PAK1 (bottom panel) in the samples. The assays were repeated an additional three times, and one-way analysis of variance tests revealed that the stimulatory effect of ALS2 and L61Rac1 on PAK1 activity was significant (p Ͻ 0.01). E15) to 1 year revealed the presence of similar levels of ALS2 that migrated as a single major species of ϳ180 kDa. This 180-kDa species co-migrated with ALS2 in transfected CHO cells and corresponds to the predicted molecular mass of ALS2. Others have also reported that ALS2 expression does not change markedly in the rodent brain after embryonic day 10 (35) . Similar immunoblots of rat cortical neurons also revealed the presence of ALS2; however, there was a small but consistent decrease in ALS2 levels in cultures that were Ͼ11 days old (Fig. 3B) .
Application of the ALS2 antibody to 2 DIV rat hippocampal and cortical neurons produced prominent staining within cell bodies; labeling of punctate structures within neurites was also detected (Fig. 4) . These results are similar to those described by others in 7 DIV rat hippocampal neurons (13) . However, in the 2-3 DIV neurons, we also detected labeling within growth cones of both axons and dendrites (Fig.  4A) ; Rac and actin are known to be enriched within growth cones. We also studied the subcellular distributions of transfected ALS2 and ALS2⌬DH by use of the myc tags, and these too localized to cell bodies, axons, and dendrites, and also within growth cones, in ways that were not noticeably different from that of endogenous ALS2 (Fig. 4B) . Transfected ALS2 therefore appears to localize to the appropriate cellular compartments in which endogenous ALS2 resides.
Growth cones are made up of two domains: the central domain and the peripheral domain. The central domain contains microtubules, whereas the peripheral domain is actin-rich, containing the most motile structures, the lamellipodia and filopodia. Co-staining for ALS2 with tubulin or actin revealed that ALS2 was present throughout the whole growth cone (Fig. 4, C-E) . We also performed double labeling for ALS2 and Rac1, and this revealed a close overlap in the distributions of the two proteins in growth cones (Fig. 4C) . These results complement the biochemical studies that demonstrate that ALS2 is a Rac GEF, and together they suggest that ALS2 may function in growth cone motility and neurite outgrowth.
ALS2 Stimulates Neurite Outgrowth-A number of GEFs that stimulate the activities of Rac, Rho, and Cdc42 GTPases have been shown to regulate neurite outgrowth (23, 24, 26, 36, 37) . We therefore examined the effect of overexpression of ALS2 on the development of axons and dendrites in rat cortical neurons. To do so, we transfected 2 DIV neurons with ALS2 or control vectors and analyzed neurite outgrowth in the cells 24 h later.
The numbers of neurites (neurite tip number per cell) were not affected by overexpression of ALS2 or ALS2⌬DH (supplemental data, Fig. S2 ). However, ALS2 significantly increased (by 1.5-fold) the length of the longest neurite (Fig. 5) . This level of stimulation in neurite outgrowth is similar to that observed by other Rac GEFs (23) . By contrast, overexpression of ALS2⌬DH had no effect on neurite outgrowth (Fig.  5) . To determine, in addition, that the ALS2-mediated stimulation of neurite outgrowth involves Rac signaling, we compared neurite outgrowth in cells co-transfected with ALS2 and either a dominant-negative Rac (N17Rac) or a dominant-negative Rab5 (N39Rab5). ALS2 stimulates both Rac activity via its central DH/PH domain and Rab5 activity via its VPS9 domain (Refs. 12-15 and see above). This approach, involving dominant-negative GTPases to dissect out pathways by which other GEFs stimulate neurite outgrowth, has been utilized successfully in many other studies (e.g. Refs. 23 and 26). Co-transfection of ALS2 with N17Rac but not N39Rab5 abrogated the stimulatory effect of ALS2 on neurite outgrowth (Fig. 5) . Thus, ALS2 promotes neurite outgrowth in rat cortical neurons, and this involves its Rac but not its Rab5 GEF activity.
Expression of N17Rac alone had no effect on neurite outgrowth, which is consistent with a number of other reports (23, 38) . However, Rac has also been shown to both promote and inhibit neurite outgrowth, and it is likely that such conflicting results are due to the different types of neurons, ages, and culture conditions used for experimentation (e.g. Refs. 39 -42) . Nevertheless, our findings that N17Rac blocks the effect of ALS2 but has no effect on neurite outgrowth alone is similar to that seen in studies with other Rac GEFs (23, 26) .
ALS2 Is a Phosphoprotein-To begin to understand the upstream mechanisms that regulate ALS2 activity, we sequenced the protein to identify phosphorylation sites. A number of GEFs are known to be phosphorylated, and this can regulate their activities; this includes roles in neurite outgrowth (e.g. Refs. 43 and 44) . ALS2 is a particularly low abundance protein (17) , and so to obtain sufficient protein for sequencing, we isolated it from transfected CHO cells. Using a combination of trypsin, chymotrypsin, and Asp-N protease digestion, we obtained 81% sequence coverage (supplemental data, Fig. S3 ). Serines 277, 492, 1335, and 1464 and threonine 510 were all unambiguously identified as phosphorylation sites; a number of other phosphopeptides were also detected, although the responsible residues could not be identified. The identified residues all precede a proline making them candidates for phosphorylation by proline-directed kinases such as those of the mitogen-activated protein kinase superfamily, the cyclin-dependent kinases (Cdks) and glycogen synthase kinase-3␣/␤. To inquire whether phosphorylation of these sites influenced ALS2 regulation of Rac activity, we constructed mutants in which serine/threonine residues were altered to alanine to preclude phosphorylation, but these mutants had no discernible effect on ALS2 Rac activity, PAK1 activity, or neurite outgrowth (supplemental data, Fig. S4 ).
DISCUSSION
Rho, Rac, and Cdc42 are key regulators in the development of axons and dendrites. They achieve this by transducing upstream signaling cues to regulate actin dynamics within the growth cone (11, 30 -34) . The activities of Rho, Rac, and Cdc42 are regulated in a variety of fashions including activation by GEFs that stimulate GTP binding and inhibition by GTPase activating proteins that promote GTP release (10) . A number of GEFs have now been shown to be involved in the development of axons and dendrites (23, 24, 26, 36, 37) . ALS2 is a recently described protein that contains three potential GEF domains (5, 6) . The carboxyl-terminal, VPS9 homology domain has been shown to act as a GEF for Rab5; Rab5 is an essential regulator of endocytosis and endosome biogenesis (12, 13) . The central region of ALS2 contains Dbl homology and pleckstrin homology (DH/PH) domains and thus resembles GEFs for Rho, Rac, and Cdc42. Immediate downstream effectors of Rac include the PAK family kinases, and Rac1-PAK1 signaling is known to modulate actin dynamics so as to regulate the growth of both axons and dendrites (30, 32) . We show here that ALS2 is present within growth cones of both axons and dendrites and that it acts as a GEF for Rac1 to stimulate PAK1 activity and neurite outgrowth. The DH/PH GEF domain is essential for this signaling because its disruption abrogates the effect on both Rac1 and PAK1 activities and on the ability of ALS2 to promote neurite outgrowth.
We also demonstrate that ALS2 is a phosphoprotein and report the identification of five cellular phosphorylation sites. All of these are Ser/ Thr-Pro motifs, which makes them targets for proline-directed kinases such as members of the stress-activated protein kinase family (c-Jun amino-terminal kinases and p38) and Cdks. Interestingly, aberrant activation of both p38 and cdk5 (a neuronal Cdk) are seen in ALS and mutant SOD1 transgenic models of ALS, and this activation may be part of mutant SOD1 toxicity (45) (46) (47) (48) (49) (50) (51) . However, mutation of these sites did not noticeably alter the effect of ALS2 on Rac activity. Whether phosphorylation regulates other ALS2 GEF (Rab5 or Ran) activities will be addressed in future studies and when the full complement of ALS2 phosphorylation sites have been identified.
Nine disease-causing mutations in ALS2 have been described in nine different autosomal recessive kindreds. All of the affected individuals are homozygous for the mutation and develop a slowly progressive, ascending upper motor neuron disorder that presents with a lower limb spasticity and can have onset in infancy, childhood, or adolescence. All of the mutations result in premature translational termination and truncation of the full-length native protein (5) (6) (7) (8) (9) . The neuropathology has not been described, but in a clinically similar genetic disorder, hereditary spastic paraplegia due to mutations in SPG4, upper motor neurons projecting into the corticospinal tract develop a dying-back axonopathy. The recessive nature of ALS2 and truncation mutations suggest that the disorder is caused by a loss of normal ALS2 function, but the function of ALS2 is unclear and the precise mechanisms by which this leads to clinically selective motor neuron degeneration are unknown.
One possibility is that the loss of ALS2 Rab5 GEF function perturbs membrane trafficking so as to induce disease. Indeed, disruptions to membrane trafficking and the Golgi are seen in mutant SOD1 transgenic mice models of ALS, and recently mutations in the vesicle-trafficking protein VAPB have been shown to cause late onset spinal muscular atrophy and ALS (52, 53) . There may even be mechanisms linking mutant SOD1 and ALS2 forms of ALS (15, 16) .
Another possibility, and one that is supported by the findings reported here, is that the loss of ALS2 Rac1 GEF function compromises proper development of motor neurons making them more susceptible to later toxic insults. Indeed, upper motor neurons are the largest in the central nervous system with the longest axons, and so any defect in axonal growth induced by the loss of ALS2 function is likely to be most severe in these cells. However, none of the above hypotheses are mutually exclusive. Whatever the mechanisms by which mutations in ALS2 induce disease, a proper understanding of ALS2 function is likely to assist in unraveling the aberrant molecular processes by which motor neurons die in ALS.
